by Shannon L. Maude, David T. Teachey, David L. Porter, and Stephan A

Slides:



Advertisements
Similar presentations
Manuscript summary Chronic Lymphoid Leukemia (CLL) Background Genetically engineering T cells Patient treatment history Engineered T cell therapy and.
Advertisements

Safe and Effective Re-Induction of Complete Remissions in Adults with Relapsed B-ALL Using 19-28z CAR CD19-Targeted T Cell Therapy Davila ML et al. Proc.
Lee DW III et al. Proc ASH 2013;Abstract 68.
T Cells Engineered with a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Produce Significant in Vivo Proliferation, Complete Responses and Long-Term.
T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia by Michael Kalos, Bruce.
Reduced-intensity allogeneic transplantation in pediatric patients ineligible for myeloablative therapy: results of the Pediatric Blood and Marrow Transplant.
Maude et al. BLOOD, 25 JUNE 2015 x VOLUME 125, NUMBER 26
The Role of Immunotherapy for the Treatment of Hematologic Malignancies Patrick Stiff MD Coleman Professor of Oncology Loyola University Medical Center.
Evidence of B Cell Immune Responses to Acute Lymphoblastic Leukemia in Murine Allogeneic Hematopoietic Stem Cell Transplantation Recipients Treated with.
Immunotherapy with CD19 CAR redirected T-cells for high risk, relapsed paediatric CD19+ acute lymphoblastic leukaemia (ALL) and other haematological malignancies.
Early Stem Cell Transplantation for Refractory Acute Leukemia after Salvage Therapy with High-Dose Etoposide and Cyclophosphamide  Asha Johny, Kevin W.
19-28z CAR T-Cell Efficacy and Toxicity in Adults With R/R B-Cell ALL
Professor John Gribben Barts Cancer Institute
Jacques F.A.P. Miller, Michel Sadelain  Cancer Cell 
Building better therapy for children with acute lymphoblastic leukemia
Gupta V, Tallman MS, Weisdorf DJ
Michael A. Pulsipher, Christina Peters, Ching-Hon Pui 
Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial.
Figure 1 Chimeric antigen receptor (CAR) structures
Alternative Allogeneic Donor Sources for Transplantation for Childhood Diseases: Unrelated Cord Blood and Haploidentical Family Donors  Mitchell S. Cairo,
Immunotherapy for Pediatric Cancer
Antibody-modified T cells: CARs take the front seat for hematologic malignancies by Marcela V. Maus, Stephan A. Grupp, David L. Porter, and Carl H. June.
T-Cell Immunity in Acute Coronary Syndromes
Will Engineered T Cells Expressing CD20 scFv Eradicate Melanoma?
CAR T cell therapy—principle and clinical trial overview
The Outcome of Sibling and Unrelated Donor Allogeneic Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia in First Remission Who Were.
CAR T cell therapy—principle and clinical trial overview
Rapid generation of combined CMV-specific CD4+ and CD8+ T-cell lines for adoptive transfer into recipients of allogeneic stem cell transplants by Georg.
Will Post-Transplantation Cell Therapies for Pediatric Patients Become Standard of Care?  Arjan C. Lankester, Franco Locatelli, Peter Bader, Eva Rettinger,
Figure 1 CAR-T-cell design
Chimerism-Based Pre-Emptive Immunotherapy with Fast Withdrawal of Immunosuppression and Donor Lymphocyte Infusions after Allogeneic Stem Cell Transplantation.
by Jayesh Mehta Blood Volume 112(2): July 15, 2008
Allogeneic Stem Cell Transplantation for Relapsed or Refractory Lymphoma after Conditioning with BEAM/Fludarabine/TBI  Alix O’Meara, Jörg Halter, Dominik.
Influence of Stem Cell Source on Outcomes of Allogeneic Reduced-Intensity Conditioning Therapy Transplants Using Haploidentical Related Donors  Kenneth.
Infused CD34+ cell dose predicts long-term survival in acute myelogenous leukemia patients who received allogeneic bone marrow transplantation from matched.
Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.
Jacob M. Rowe  Biology of Blood and Marrow Transplantation 
Purification of CD4+ T Cells for Adoptive Immunotherapy after Allogeneic Hematopoietic Stem Cell Transplantation  Evgeny Klyuchnikov, Andreas Sputtek,
Immunotherapy for acute lymphoblastic leukemia: from famine to feast
Leukemia Lineage-Specific Chimerism Analysis and Molecular Monitoring Improve Outcome of Donor Lymphocyte Infusions  Darius Sairafi, Mats Remberger, Michael.
The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Treatment of Follicular Lymphoma: An Evidence-Based Review  Denise M.
Favorable Outcome for Infant Acute Lymphoblastic Leukemia after Hematopoietic Stem Cell Transplantation  David A. Jacobsohn, Brad Hewlett, Elaine Morgan,
Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial.
A Phase I/II Study of Chemotherapy Followed by Donor Lymphocyte Infusion plus Interleukin-2 for Relapsed Acute Leukemia after Allogeneic Hematopoietic.
The Other Face of Chimeric Antigen Receptors
Volume 26, Issue 4, Pages (April 2018)
Research Techniques Made Simple: CAR T-Cell Therapy
Allogeneic Hematopoietic Stem Cell Transplantation in Adult Acute Lymphocytic Leukemia: Impact of Donor Source on Survival  Priya Kumar, Todd E. Defor,
Transplantation Conditioning Regimens and Outcomes after Allogeneic Hematopoietic Cell Transplantation in Children and Adolescents with Acute Lymphoblastic.
Allogeneic Transplantation for Pediatric Acute Lymphoblastic Leukemia: The Emerging Role of Peritransplantation Minimal Residual Disease/Chimerism Monitoring.
Prognostic Limitations of Donor T Cell Chimerism after Myeloablative Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic.
Volume 23, Issue 1, Pages (January 2015)
Chimeric Antigen Receptor T Cells and Hematopoietic Cell Transplantation: How Not to Put the CART Before the Horse  Saad S. Kenderian, David L. Porter,
Clinical Endpoints in Allogeneic Hematopoietic Stem Cell Transplantation Studies: The Cost of Freedom  Haesook T. Kim, Philippe Armand  Biology of Blood.
Allogeneic Bone Marrow Transplantation in First Remission for Children with Ultra-high- risk Features of Acute Lymphoblastic Leukemia: A Children’s Oncology.
Chimeric antigen receptor T-cell therapy for solid tumors
Proceedings from the National Cancer Institute’s Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic.
Chimeric Antigen Receptor–Modified T Cells: Clinical Translation in Stem Cell Transplantation and Beyond  Stanley R. Riddell, Michael C. Jensen, Carl.
Allogeneic Hematopoietic Stem Cell Transplantation in FLT3-ITD–Positive Acute Myelogenous Leukemia: The Role for FLT3 Tyrosine Kinase Inhibitors Post-
Molecular Therapy  Volume 21, Pages S247-S248 (May 2013)
Eliane Gluckman  Experimental Hematology 
T cells and T-cell receptors in acute renal failure
The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Therapy of Acute Lymphoblastic Leukemia in Adults: An Evidence-based.
Hematopoietic Cell Transplantation for Adult Patients With Myelodysplastic Syndromes and Myeloproliferative Disorders  Martin Benesch, MD, H. Joachim.
Fig. 1 Engineered T cells: design of TCR versus CAR T cells.
Mary Eapen  Biology of Blood and Marrow Transplantation 
CAR T cell immunotherapy for human cancer
Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia by David L. Porter, Wei-Ting.
Chimeric antigen receptor–modified T cells: CD19 and the road beyond
Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and.
Presentation transcript:

CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia by Shannon L. Maude, David T. Teachey, David L. Porter, and Stephan A. Grupp Blood Volume 125(26):4017-4023 June 25, 2015 ©2015 by American Society of Hematology

CAR structure, according to signaling domains. CAR structure, according to signaling domains. CAR molecules link an extracellular single-chain variable fragment (scFv) to intracellular signaling domains. The intracellular component includes the CD3ζ intracellular signaling domain of the T-cell receptor either alone (first generation) or in combination with 1 (second generation) or 2 (third generation) costimulatory domains. Reprinted with permission from Maus et al.19 Shannon L. Maude et al. Blood 2015;125:4017-4023 ©2015 by American Society of Hematology

Second-generation CAR used in current clinical studies at Penn and CHOP. CTL, cytotoxic T lymphocyte; MHC, major histocompatibility complex. Second-generation CAR used in current clinical studies at Penn and CHOP. CTL, cytotoxic T lymphocyte; MHC, major histocompatibility complex. Reprinted with permission from Barrett et al.77 © Sue Seif Shannon L. Maude et al. Blood 2015;125:4017-4023 ©2015 by American Society of Hematology

Event-free survival in 30 children and adults treated with CTL019 therapy. Event-free survival in 30 children and adults treated with CTL019 therapy. Of this group, 5 patients who entered a CR went on to further therapy, 3 of whom received an allogeneic bone marrow transplant. The fourth had refractory T-cell ALL aberrantly expressing CD19, entered remission after CTL019, and subsequently underwent donor lymphocyte infusion. She remains in remission >1 year later. The fifth patient developed myelodysplastic syndrome and received therapy for this condition (this was scored as an event, but she did receive further therapy in ALL remission and was counted among the 5). The rest have not received further therapy to consolidate their remissions. EFS, event-free survival. Figure adapted from Maude et al26 with permission. Shannon L. Maude et al. Blood 2015;125:4017-4023 ©2015 by American Society of Hematology